REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy
REal-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra® Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Many Locations, China
-
-
-
-
-
Many Locations, Croatia
-
-
-
-
-
Many Locations, France
-
-
-
-
-
Many Locations, Germany
-
-
-
-
-
Many Locations, Hungary
-
-
-
-
-
Many Locations, Indonesia
-
-
-
-
-
Many Locations, Korea, Republic of
-
-
-
-
-
Many Locations, Malaysia
-
-
-
-
-
Many Locations, Poland
-
-
-
-
-
Many Locations, Saudi Arabia
-
-
-
-
-
Many Locations, Singapore
-
-
-
-
-
Many Locations, South Africa
-
-
-
-
-
Many Locations, Spain
-
-
-
-
-
Many Locations, Sweden
-
-
-
-
-
Many Locations, Thailand
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Outpatients with diagnosis of erectile dysfunction, decision taken by the investigator to prescribe Vardenafil.
Exclusion Criteria:
- Exclusion criteria must be read in conjunction with the local product information. All contraindications listed in the local product information are applicable.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
|
Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Physician's assessment of safety (incidence of adverse events)
Time Frame: During observation period
|
During observation period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Severity of ED symptoms
Time Frame: End of study
|
End of study
|
|
General quality of partnership as assessed by patient
Time Frame: Initial visit and after 3, 6, 9 and 12 months
|
Initial visit and after 3, 6, 9 and 12 months
|
|
General quality of partnership as assessed by partner
Time Frame: Initial visit and after 3, 6, 9 and 12 months
|
Initial visit and after 3, 6, 9 and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 12805
- REPEAT (Company Internal)
- LV0602 (Other Identifier: Company Internal)
- 12942 - LV0602KR (Other Identifier: Company Internal)
- 12975 - LV0602HR (Other Identifier: Company Internal)
- 12976 - LV0602CN (Other Identifier: Company Internal)
- 12977 - LV0602SG (Other Identifier: Company Internal)
- 13047 - LV0602SE (Other Identifier: Company Internal)
- 13048 - LV0602ZA (Other Identifier: Company Internal)
- 13067 - LV0602HU (Other Identifier: Company Internal)
- 13093 - LV0602MY (Other Identifier: Company Internal)
- 13112 - LV0602ID (Other Identifier: Company Internal)
- 13208 - LV0602TH (Other Identifier: Company Internal)
- 13416 - LV0602ES (Other Identifier: Company Internal)
- 13417 - LV0602SA (Other Identifier: Company Internal)
- 13600 - LV0602PL (Other Identifier: Company Internal)
- 14525 - LV0602FR (Other Identifier: Company Internal)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.